Skip to main content

Peer Review reports

From: Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy

Original Submission
13 Apr 2015 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
16 Feb 2016 Editorially accepted
26 Feb 2016 Article published 10.1186/s12885-016-2186-4

You can find further information about peer review here.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us